Prostate-specific antigen velocity and prostate cancer gleason grade and stage

Cancer

Volumn 109, Issue 8, 2007, Pages 1689-1695

  Pinsky, Paul F ^a   Andriole, Gerald ^b   Crawford, E David ^c   Chia, David ^d   Kramer, Barnett S ^e   Grubb, Robert ^b   Greenlee, Robert ^f   Gohagan, John K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Marsrifield Clinic Research and Education Foundation   (United States)

Author keywords

Gleason score; Pathologic stage; Prostate cancer; Prostate specific antigen; Prostate specific antigen velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; DEMOGRAPHY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; UNIVARIATE ANALYSIS;

AGED; CLINICAL TRIALS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 34247162236     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22558     Document Type: Article

References (14)

1. Miller DC, Hafez KS, Stewart A, et al. Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base. Cancer. 2003;98:1169-1178.
2. D'Amico AV, Chen M, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
3. Carter HB, Ferruci L, Kettermann A, et al. Detection of life-threatening prostate-cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98:1521-1527.
4. Patel DA, Presti JC, McNeal JE, et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol. 2005;23:6157-6162.
5. Goluboff ET, Heitjan DF, DeVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol. 1997;158:1876-1878.
6. Thiel R, Pearson JD, Epstein JI, Walsh PC, Carter HB. Role of prostate specific antigen velocity in prediction of final pathologic state in men with localized prostate cancer. Urology. 1997;49:716-720.
7. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529-534.
8. Schroder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol. 2006;49:460-465.
9. Berger AP, Deibl M, Steiner H, et al. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate. 2005;64:240-245.
10. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colon and Ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21:273S-309S.
11. Andriole GL, Levin DE, Crawford ED, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round. J Natl Cancer Inst. 2005;97:433-438.
12. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
13. Zackrisson B, Ulleryd P, Aus G, Lilja H, Sandberg T, Hugosson J. Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection. Urology. 2003;62:278-281.
14. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology. 1997;50:239-243.